Valentina Guatibonza-Garcia
Overview
Explore the profile of Valentina Guatibonza-Garcia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kouvari M, Valenzuela-Vallejo L, Guatibonza-Garcia V, Verrastro O, Axarloglou E, Mylonakis S, et al.
Clin Nutr
. 2024 Oct;
43(12):101-108.
PMID: 39442390
Background & Aims: The available literature on the effect of apolipoprotein C-III (ApoC-III) inhibition in MASLD reveals inconsistencies. The aim of the present work was to examine levels of ApoC-III...
2.
Boutari C, Stefanakis K, Simati S, Guatibonza-Garcia V, Valenzuela-Vallejo L, Anastasiou I, et al.
Cardiovasc Diabetol
. 2024 May;
23(1):174.
PMID: 38762719
Background: Growth differentiation factor 15 (GDF15) is a mitokine, the role of which, total or H-specific, in modulating energy metabolism and homeostasis in obesity-related diseases, such as metabolic dysfunction associated...
3.
Valenzuela-Vallejo L, Chrysafi P, Kouvari M, Guatibonza-Garcia V, Mylonakis S, Katsarou A, et al.
Metabolism
. 2023 Sep;
148:155694.
PMID: 37757973
Background: The role of metabolic/inflammatory hormonal systems in metabolic dysfunction associated steatotic liver disease (MASLD) remains to be fully elucidated. Purpose: To report the levels of the novel total and...
4.
Kouvari M, Mylonakis S, Katsarou A, Valenzuela-Vallejo L, Guatibonza-Garcia V, Kokkorakis M, et al.
Diabetes Res Clin Pract
. 2023 Aug;
203:110870.
PMID: 37567510
Aims: A new non-invasive tool (NIT) for non-alcoholic fatty liver disease (NAFLD) proposed in 2022 by the multi-ethnic Dallas Heart Study, i.e. the Dallas Steatosis Index (DSI), was validated herein...
5.
Kouvari M, Valenzuela-Vallejo L, Guatibonza-Garcia V, Polyzos S, Deng Y, Kokkorakis M, et al.
Metabolism
. 2023 Aug;
147:155666.
PMID: 37527759
Background: Non-invasive tools (NIT) for metabolic-dysfunction associated liver disease (MASLD) screening or diagnosis need to be thoroughly validated using liver biopsies. Purpose: To externally validate NITs designed to differentiate the...
6.
Gaete P, Nieves-Barreto L, Guatibonza-Garcia V, Losada-Barragan M, Vargas-Sanchez K, Mendivil C
Sci Rep
. 2023 Jul;
13(1):11573.
PMID: 37463952
There is great interest on medium chain fatty acids (MCFA) for cardiovascular health. We explored the effects of MCFA on the expression of lipid metabolism and inflammatory genes in macrophages,...
7.
Mendivil C, Amaya-Montoya M, Hernandez-Vargas J, Ramirez-Garcia N, Herrera-Parra L, Guatibonza-Garcia V, et al.
Front Endocrinol (Lausanne)
. 2023 Feb;
14:1073833.
PMID: 36742410
Objective: The magnitude of the mortality benefit conferred by good integral metabolic control in diabetes in not sufficiently known, especially among Latin American patients. We prospectively studied the association between...
8.
Valenzuela-Vallejo L, Guatibonza-Garcia V, Mantzoros C
Metabolism
. 2022 Jul;
136:155248.
PMID: 35803320
Non-Alcoholic Fatty Liver Disease (NAFLD) is a highly prevalent disease and unmet clinical need that we have recently proposed to be renamed for simplicity and accuracy as Fatty Liver Disease...
9.
Mendivil C, Amaya-Montoya M, Hernandez-Vargas J, Ramirez-Garcia N, Romero-Diaz C, Perez-Londono A, et al.
Diabetes Res Clin Pract
. 2022 Mar;
186:109823.
PMID: 35271878
Aims: To assess the achievement of essential treatment goals among patients with diabetes in Colombia. Methods: We analyzed data from a nationwide registry of all individuals with diagnosed diabetes, hypertension...
10.
Guatibonza-Garcia V, Gaete P, Perez-Londono A, Puerto-Baracaldo D, Gutierrez-Romero S, Mendivil C, et al.
World J Gastroenterol
. 2021 Aug;
27(29):4890-4899.
PMID: 34447233
Background: Primary biliary cholangitis (PBC) is a serious disease that causes significant morbidity. PBC is confirmed with liver biopsy but autoantibodies are frequently used as proxies for diagnosis. The performance...